TY - JOUR
T1 - Combining L-Arginine with vitamin C improves long-COVID symptoms
T2 - The LINCOLN Survey
AU - Izzo, Raffaele
AU - Trimarco, Valentina
AU - Mone, Pasquale
AU - Aloè, Teresita
AU - Capra Marzani, Massimo
AU - Diana, Antonio
AU - Fazio, Giovanni
AU - Mallardo, Mario
AU - Maniscalco, Mauro
AU - Marazzi, Giuseppe
AU - Messina, Nunzia
AU - Mininni, Simone
AU - Mussi, Chiara
AU - Pelaia, Girolamo
AU - Pennisi, Alfio
AU - Santus, Pierachille
AU - Scarpelli, Francesco
AU - Tursi, Francesco
AU - Zanforlin, Alessandro
AU - Santulli, Gaetano
AU - Trimarco, Bruno
N1 - Funding Information:
We thank Dr. J. Gambardella for helpful discussion. The study did not receive any funding.
Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/9
Y1 - 2022/9
N2 - Introduction: Recent evidence suggests that oxidative stress and endothelial dysfunction play critical roles in the pathophysiology of COVID-19 and Long-COVID. We hypothesized that a supplementation combining L-Arginine (to improve endothelial function) and Vitamin C (to reduce oxidation) could have favorable effects on Long-COVID symptoms. Methods: We designed a survey (LINCOLN: L-Arginine and Vitamin C improves Long-COVID), assessing several symptoms that have been associated with Long-COVID to be administered nationwide to COVID-19 survivors; the survey also included effort perception, measured using the Borg scale. Patients receiving the survey were divided in two groups, with a 2:1 ratio: the first group included patients that received L-Arginine + Vitamin C, whereas the second group received a multivitamin combination (alternative treatment). Results: 1390 successfully completed the survey. Following a 30-day treatment in both groups, the survey revealed that patients in the L-Arginine + Vitamin C treatment arm had significantly lower scores compared to patients who had received the multivitamin combination. There were no other significant differences between the two groups. When examining effort perception, we observed a significantly lower value (p < 0.0001) in patients receiving L-Arginine + Vitamin C compared to the alternative-treatment arm. Conclusions: Taken together, our surveys indicates that the supplementation with L-Arginine + Vitamin C has beneficial effects in Long-COVID, in terms of attenuating its typical symptoms and improving effort perception.
AB - Introduction: Recent evidence suggests that oxidative stress and endothelial dysfunction play critical roles in the pathophysiology of COVID-19 and Long-COVID. We hypothesized that a supplementation combining L-Arginine (to improve endothelial function) and Vitamin C (to reduce oxidation) could have favorable effects on Long-COVID symptoms. Methods: We designed a survey (LINCOLN: L-Arginine and Vitamin C improves Long-COVID), assessing several symptoms that have been associated with Long-COVID to be administered nationwide to COVID-19 survivors; the survey also included effort perception, measured using the Borg scale. Patients receiving the survey were divided in two groups, with a 2:1 ratio: the first group included patients that received L-Arginine + Vitamin C, whereas the second group received a multivitamin combination (alternative treatment). Results: 1390 successfully completed the survey. Following a 30-day treatment in both groups, the survey revealed that patients in the L-Arginine + Vitamin C treatment arm had significantly lower scores compared to patients who had received the multivitamin combination. There were no other significant differences between the two groups. When examining effort perception, we observed a significantly lower value (p < 0.0001) in patients receiving L-Arginine + Vitamin C compared to the alternative-treatment arm. Conclusions: Taken together, our surveys indicates that the supplementation with L-Arginine + Vitamin C has beneficial effects in Long-COVID, in terms of attenuating its typical symptoms and improving effort perception.
KW - Ascorbic acid
KW - COVID-19
KW - Endothelial dysfunction
KW - L-Arginine
KW - Long-COVID
KW - Oxidative stress
KW - Survey
UR - http://www.scopus.com/inward/record.url?scp=85136552939&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136552939&partnerID=8YFLogxK
U2 - 10.1016/j.phrs.2022.106360
DO - 10.1016/j.phrs.2022.106360
M3 - Article
C2 - 35868478
AN - SCOPUS:85136552939
SN - 1043-6618
VL - 183
JO - Pharmacological Research
JF - Pharmacological Research
M1 - 106360
ER -